Table 1

Clonal involvement of sorted IgL+ and IgL- cells.
Patient
 Translocation
 %CD19+ cells
of all BM MNCs
 %IgL+ cells of
all CD19+ cells
 Population
 % FISH+
A
 dic(7;12)(p11;p11)
 76
 15
 CD19+IgL-
 99




CD19+IgL+
 1,9
B
 t(12;21)(p13;q22)
 63
 12
 CD19+IgL-
 99




CD19+IgL+
 2,7
C
 t(1;19)(q23;p13)
 84
 7
 CD19+IgL-
 98




CD19+IgL+
 27
D
 High
hyperdiploidy
 87
 7
 CD19+IgL-
 99




CD19+IgL+
 25
E
 t(12;21)(p13;q22)
 91
 2
 CD19+IgL-
 100




CD19+IgL+
 3
Patient
 WBC ×109/l
 %CD19+ cells
of all PB MNCs
 %IgL+ cells of
all CD19+ cells
 Population
 % FISH+
A
 3.5
 54
 52
 CD19+IgL-
 97




CD19+IgL+
 4,2
B
 2.1
 9,2
 90
 CD19+IgL-
 ND




CD19+IgL+
 ND
C
 70
 57
 20
 CD19+IgL-
 96




CD19+IgL+
 33
D
 23
 81
 12
 CD19+IgL-
 99




CD19+IgL+
 17
E
 29
 82
 5
 CD19+IgL-
 100




CD19+IgL+
 8

MNCs from five patients (A-E) analyzed for phenotype by FACS and clonal involvement in IgL+ and IgL- cells by detection of the corresponding chromosome abnormality by FISH. Upper panel shows data from BM at diagnosis and lower panel from PB at diagnosis.

Hansson et al. Molecular Cancer 2008 7:67   doi:10.1186/1476-4598-7-67